Trials / Completed
CompletedNCT00200356
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 401 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edaravone | Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening. |
| DRUG | Sodium Ozagrel | Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening. |
Timeline
- Start date
- 2004-08-01
- Completion
- 2006-10-01
- First posted
- 2005-09-20
- Last updated
- 2026-01-07
- Results posted
- 2013-01-15
Source: ClinicalTrials.gov record NCT00200356. Inclusion in this directory is not an endorsement.